New Horizon Medical Solutions (NHMS), a leader in advanced wound care technologies, announced a strategic collaboration with Soring, the U.S. affiliate of Söring (Germany), to distribute the SONOCA 185 Ultrasonic-Assisted Wound (UAW) debridement system. This partnership aims to improve treatment outcomes for chronic and acute wounds across various medical settings by integrating ultrasonic debridement with NHMS's placental allograft products.
The Söring UAW system consists of an ultrasonic generator and instrument designed for debridement and wound cleansing. It removes fibrin tissues, including necroses, fibrin, scab, and pus, and breaks up biofilms. The device is indicated for conditions such as diabetic foot syndrome, decubitus ulcers, burns, post-surgical wounds, and post-traumatic wounds, improving wound status and promoting healing.
Jeffrey Alan Niezgoda, MD, FACHM, MAPWCA, CHWS, Chief Medical Officer of Kent Imaging and board member of NHMS, highlighted the synergy between the UAW device and other technologies: "The use of SONOCA 185 and the UAW instruments for Ultrasonic Wound Debridement guided by SnapshotGLO and monitored by SnapshotNIR can significantly improve wound management and lead to better patient outcomes. These devices synergistically optimize wound bed preparation prior to CAMPs application."
Will Hall, CEO of NHMS, emphasized the strategic importance of the collaboration: "This collaboration reflects our belief that the future of wound care lies in combining advanced technology with evidence-based clinical solutions. By bringing Söring's ultrasonic system into our portfolio, we're expanding access to innovative tools that address critical gaps in treatment while improving efficiency and outcomes across care settings."
The partnership addresses a critical need in wound care: effective debridement is essential for preparing the wound bed for advanced therapies. NHMS's portfolio includes amniotic membranes, placental tissues, and skin grafts for chronic wounds, surgical reconstruction, burns, and orthopedic procedures. The addition of ultrasonic debridement is expected to enhance the efficacy of these products by ensuring optimal wound bed preparation.
Söring, founded in 1985 and headquartered in Germany, specializes in ultrasonic tissue resection and ablation. The company develops medical technologies used globally, with a focus on intuitive user experience and direct service. This collaboration marks a step forward in making ultrasonic debridement more accessible in the U.S. market.
For more information, visit www.nhmedical.com.
